Relay Therapeutics, Inc. (RLAY) stock
RLAYNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$17.27−0.82 (-4.53%)
Close on Nov 16, 2026Market cap $3.78BP/E –Yield –
Relay Therapeutics r&d expenses
Research and development expenses are spending on new products and technology.
Relay Therapeutics's R&D Expenses for the twelve months ending Sep 30, 2026 was $279.60M, up 2.0% year over year. For fiscal 2025 it was $261.38M, down 18.1% from the year before. The highest annual figure on record is $330.02M in fiscal 2023.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $261.38M | -18.1% |
| FY2024 | Dec 31, 2024 | $319.09M | -3.3% |
| FY2023 | Dec 31, 2023 | $330.02M | +34.0% |
| FY2022 | Dec 31, 2022 | $246.36M | +42.7% |
| FY2021 | Dec 31, 2021 | $172.65M | +72.9% |
| FY2020 | Dec 31, 2020 | $99.86M | +42.0% |
| FY2019 | Dec 31, 2019 | $70.31M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $77.14M | +13.0% |
| Q2 FY2026 | Jun 30, 2026 | $76.48M | +19.7% |
| Q1 FY2026 | Mar 31, 2026 | $70.56M | -4.4% |
| Q4 FY2025 | Dec 31, 2025 | $55.42M | -18.6% |
| Q3 FY2025 | Sep 30, 2025 | $68.26M | -10.9% |
| Q2 FY2025 | Jun 30, 2025 | $63.90M | -30.5% |
| Q1 FY2025 | Mar 31, 2025 | $73.81M | -10.4% |
| Q4 FY2024 | Dec 31, 2024 | $68.08M | -12.2% |
| Q3 FY2024 | Sep 30, 2024 | $76.62M | -6.0% |
| Q2 FY2024 | Jun 30, 2024 | $91.99M | +4.3% |
| Q1 FY2024 | Mar 31, 2024 | $82.40M | -0.5% |
| Q4 FY2023 | Dec 31, 2023 | $77.50M | +15.2% |
| Q3 FY2023 | Sep 30, 2023 | $81.49M | +21.8% |
| Q2 FY2023 | Jun 30, 2023 | $88.20M | +45.8% |
| Q1 FY2023 | Mar 31, 2023 | $82.83M | +60.3% |
| Q4 FY2022 | Dec 31, 2022 | $67.28M | +29.6% |
| Q3 FY2022 | Sep 30, 2022 | $66.90M | +48.8% |
| Q2 FY2022 | Jun 30, 2022 | $60.51M | +34.0% |
| Q1 FY2022 | Mar 31, 2022 | $51.67M | +68.7% |
| Q4 FY2021 | Dec 31, 2021 | $51.91M | +61.6% |
| Q3 FY2021 | Sep 30, 2021 | $44.97M | +84.5% |
| Q2 FY2021 | Jun 30, 2021 | $45.15M | +108.4% |
| Q1 FY2021 | Mar 31, 2021 | $30.62M | +41.1% |
| Q4 FY2020 | Dec 31, 2020 | $32.12M | +43.4% |
| Q3 FY2020 | Sep 30, 2020 | $24.38M | +33.5% |
| Q2 FY2020 | Jun 30, 2020 | $21.67M | +32.1% |
| Q1 FY2020 | Mar 31, 2020 | $21.70M | – |
| Q4 FY2019 | Dec 31, 2019 | $22.41M | – |
| Q3 FY2019 | Sep 30, 2019 | $18.26M | – |
| Q2 FY2019 | Jun 30, 2019 | $16.40M | – |
See a number that looks wrong?